Russia To Test ‘Sputnik V’ COVID-19 Vaccine In 40K Human Subjects
The Russian government said Thursday it will begin clinical trials next week for its already-registered COVID-19 vaccine and it will involve tens of thousands of human subjects.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, told reporters the trials will be done in several countries, including Russia, Saudi Arabia and the United Arab Emirates. He said the trials will involve 40,000 humans.
Dmitriev also said Russia hopes to have detailed scientific data published in a major journal sometime this month.
Russian President Vladimir Putin announced earlier this month that Moscow had registered the "Sputnik V" vaccine and said he'd even administered it to one of his daughters. The announcement was met with surprise and skepticism in the medical community, as the vaccine had not been put through late-stage clinical trials, which is a key phase for any vaccine development.
The World Health Organization said Thursday it has begun discussions with Russia about testing the vaccine.
"This concern that we have around safety and efficacy is not specifically for the Russia vaccine, it's for all of the vaccines under development," said Catherine Smallwood, WHO Europe's senior emergency official. "It's essential we don't cut corners in safety or efficacy."
"The end of the pandemic will be the day when everyone of us will take the responsibility and have been learning how to behave with the virus," WHO Europe Regional Director Hans Kluge cautioned. "And that depends on us, that day can even be tomorrow."
Moscow has not yet released any scientific data associated with the Sputnik V vaccine and most experts continue to be skeptical of its safety or ability to ward off the coronavirus.


Survey Shows Biggest Jump In Investor Optimism Since March 2020
Dow Jones Lags As Jobless Claims Spike, But Nasdaq Eyes New Closing High
Advisor News
- How advisors can prepare clients for an uncertain retirement landscape
- Investors aren’t waiting out uncertainty
- Transamerica and Advo(k)ate Advisors launch pooled employer plan
- ‘I wish I’d met him sooner:’ Karlan Tucker remembered for integrity, faith
- Why women must be more engaged in investing
More Advisor NewsAnnuity News
- AM Best Revises Outlooks to Negative for Subsidiaries of Group 1001 Insurance Holdings, LLC
- Market-value adjusted annuities: Key considerations for advisors
- Private equity’s next play in insurance
- Immediate Care Plan: A new solution for funding LTC
- Delaware Life Launches a New Bonus Fixed Index Annuity Built for Growth, Protection, and Flexibility
More Annuity NewsHealth/Employee Benefits News
- Studies from Harvard University T.H. Chan School of Public Health Describe New Findings in Managed Care [Preconception, prenatal and postnatal exposure to gaseous air pollutants (NO2, O3) and neurodevelopmental disorders in children among …]: Managed Care
- Studies from Harvard T.H. Chan School of Public Health Further Understanding of Managed Care (Structural Racism-related State Laws and Healthcare Access Among Black, Latine, and White Us Adults): Managed Care
- Data on Managed Care Reported by Researchers at University of California Berkeley (Welfare Program Participation Among Us Farmworkers Evidence From Three National Surveys): Managed Care
- ON MEDICAID'S 61ST ANNIVERSARY, A REMINDER PENNSYLVANIA REPUBLICANS CONTINUE TO PUSH DEVASTATING HEALTHCARE CUTS
- ON 61ST ANNIVERSARY OF MEDICAID, 10,000 FEWER ALASKANS HAVE COVERAGE AFTER PASSAGE OF DAN SULLIVAN'S AGENDA
More Health/Employee Benefits NewsLife Insurance News
- AM Best Revises Outlooks to Negative for Subsidiaries of Group 1001 Insurance Holdings, LLC
- Court sides with Ameritas in denying $4M STOLI payout to Wells Fargo
- AM Best Removes From Under Review With Positive Implications and Upgrades Credit Ratings of The Fortegra Group, Inc.’s Insurance Subsidiaries
- Yancey Jr., Delos Harley
- Vincent Esparza CFP, CLU joins Wilde Wealth Management Group as Senior Wealth Advisor
More Life Insurance News